S&P Futures
4,291.50 -6.75 (-0.16%) Dow Futures
33,855.00 -18.00 (-0.05%) Nasdaq Futures
13,658.00 -23.25 (-0.17%) Russell 2000 Futures
2,021.70 -2.10 (-0.10%) Crude Oil
88.87 -0.54 (-0.60%) Gold
1,795.90 -2.20 (-0.12%)
Fresenius Medical Care AG & Co. KGaA (FMCQF)
Chart Events
Performance Outlook
| Previous Close | 37.45 |
| Open | 37.45 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 37.45 - 37.45 |
| 52 Week Range | 37.45 - 79.91 |
| Volume | |
| Avg. Volume | 4,738 |
| Market Cap | 10.973B |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | 10.51 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.41 (3.07%) |
| Ex-Dividend Date | May 13, 2022 |
| 1y Target Est | N/A |
- Moody's
Fresenius Medical Care Holdings, Inc. -- Moody's affirms Fresenius Medical Care Holdings' Baa3 rating; outlook stable
Rating Action: Moody's affirms Fresenius Medical Care Holdings' Baa3 rating; outlook stableGlobal Credit Research - 15 Aug 2022Frankfurt am Main, August 15, 2022 -- Moody's Investors Service ("Moody's") has today affirmed Fresenius Medical Care Holdings, Inc.'s (FMCH or the company) Baa3 long-term issuer rating. The outlook remains stable.RATINGS RATIONALEToday's rating action reflects the company's standalone credit profile, as well as the fact that FMCH is a significant subsidiary of Fresenius Medical Care AG & Co. KGaA (FMC, Baa3 stable) because this entity owns and consolidates all the US operating subsidiaries of the parent. FMCH contributed around 70% of the parent company's revenue and around 76% of its Moody's adjusted EBITDA in 2021.FMCH's standalone operating profitability and credit metrics are relatively similar to those of FMC, and they are not likely to change significantly over time.
- Moody's
Fresenius Finance Ireland II Plc -- Moody's affirms Fresenius SE's Baa3 rating; outlook stable
Rating Action: Moody's affirms Fresenius SE's Baa3 rating; outlook stableGlobal Credit Research - 15 Aug 2022Frankfurt am Main, August 15, 2022 -- Moody's Investors Service ("Moody's") has today affirmed Fresenius SE & Co. KGaA's (FSE or the company) Baa3 long-term issuer rating. During the period of subdued operating performance, which will likely last until end of 2023, Moody's expects FSE will remain fully committed to its investment grade rating by prioritizing its public commitment to the 3-3.5x net leverage range over capital allocation to M&A and shareholders' distribution. The rating as of today is weakly positioned.
- Moody's
Fresenius Medical Care US Finance III, Inc. -- Moody's affirms Fresenius Medical Care's Baa3 rating; outlook stable
Rating Action: Moody's affirms Fresenius Medical Care's Baa3 rating; outlook stableGlobal Credit Research - 15 Aug 2022Frankfurt am Main, August 15, 2022 -- Moody's Investors Service ("Moody's") has today affirmed Fresenius Medical Care AG & Co. KGaA's (FMC or the company) Baa3 long-term issuer rating. The outlook remains stable.A full list of affected ratings can be found at the end of this press release.RATINGS RATIONALEToday's rating affirmation with stable outlook reflects Moody's expectations that current operating headwinds are mostly temporary. During this period of subdued operating performance, which will likely last until end of 2023, Moody's expects FMC will remain fully committed to its investment grade rating by prioritizing its public commitment to the 3-3.5x net leverage range over capital allocation to M&A and shareholders' distribution.
